These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Pathogenic role of Fgf23 in Hyp mice. Liu S; Zhou J; Tang W; Jiang X; Rowe DW; Quarles LD Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E38-49. PubMed ID: 16449303 [TBL] [Abstract][Full Text] [Related]
7. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Quarles LD Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601 [TBL] [Abstract][Full Text] [Related]
8. [From gene to disease; hypophosphataemic rickets and the PHEX gene]. Jansen M; van Dael CM; Verrijn Stuart AA; van der Hout AH; Rump P Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1390-4. PubMed ID: 16841587 [TBL] [Abstract][Full Text] [Related]
9. [Molecular biology in regulation of kidney functions: FGF23 (fibroblast growth factor 23)]. Tanaka H Nihon Rinsho; 2006 Feb; 64 Suppl 2():322-6. PubMed ID: 16523910 [No Abstract] [Full Text] [Related]
10. The PEX gene: its role in X-linked rickets, osteomalacia, and bone mineral metabolism. Rowe PS Exp Nephrol; 1997; 5(5):355-63. PubMed ID: 9386970 [No Abstract] [Full Text] [Related]
11. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740 [TBL] [Abstract][Full Text] [Related]
12. [Endocrine diseases accompanied by hypophosphatemia or hyperphosphatemia]. Nakayama K Nihon Rinsho; 2006 Sep; Suppl 3():542-52. PubMed ID: 17022606 [No Abstract] [Full Text] [Related]
14. A familial disorder with low bone density and renal phosphate wasting. Grondel IM; van der Deure J; Zanen AL; Dogger M; van den Heuvel LP Eur J Intern Med; 2009 Sep; 20(5):503-8. PubMed ID: 19712854 [TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 23 and its receptors. Yu X; White KE Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372 [TBL] [Abstract][Full Text] [Related]
16. Genetic advances, biochemical and clinical features and critical approach to treatment of patients with X-linked hypophosphatemic rickets. Baroncelli GI; Bertelloni S; Sodini F; Galli L; Vanacore T; Fiore L; Saggese G Pediatr Endocrinol Rev; 2004 Jun; 1(4):361-79. PubMed ID: 16437029 [TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. Kida Y N Engl J Med; 2003 Jul; 349(5):505-6; author reply 505-6. PubMed ID: 12890852 [No Abstract] [Full Text] [Related]
19. Use of the transgenic approach to determine the role of DMP1 in phosphate regulation. Lu Y; Liu S; Xie Y; Yu S; Quarles L; Bonewald LF; Feng JQ J Musculoskelet Neuronal Interact; 2007; 7(4):309. PubMed ID: 18094487 [No Abstract] [Full Text] [Related]
20. [Fibroblast growth factor 23 (FGF 23): a new fosfaturic hormone?]. Negri AL Nefrologia; 2003; 23(6):478-81. PubMed ID: 15002780 [No Abstract] [Full Text] [Related] [Next] [New Search]